Home › NCT04707872
Trifecta-Heart cfDNA-MMDx Study
RecruitingObservational study
Trifecta-Heart cfDNA-MMDX Study: Comparing the DD-cfDNA Test to MMDx Microarray Test and Central HLA Antibody Test
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * All heart transplant recipients undergoing a biopsy for clinical indications and protocol biopsies, as determined by their physician or surgeon, will be eligible to enroll in the study. * Patients are enrolled based on standard of care biopsies, including surveillance biopsies in high-risk patients, with informed consent. Exclusion Criteria: * Patients will be excluded from the study if they decline participation * Are unable to give informed consent. * Recipients of multiple organs.
About the study
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
What is being tested
- MMDx diagnostic test (diagnostic test)
- Prospera (diagnostic test)
- HLA antibody (diagnostic test)
Sponsor: University of Alberta · Participants: 300 · Started: Jun 1, 2021
Contact the study team
- Konrad Famulski, PhD · Phone: 1 780 782 9463
- Robert Polakowski, PhD · Phone: 1 780 492 5091
Official record on ClinicalTrials.gov — NCT04707872
Locations in the U.S.
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.